Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Rocbrutinib (LP-168) in Healthy Subjects
NCT05917964Phase 1Completed
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rocbrutinib in mantle cell lymphoma (MCL) (2 cohorts), sponsored by Lupeng Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Time t, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity and 2 more. Started Jun 2023; status: completed.
02
Drugs
rocbrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05917964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917964.